US EditionOzempic for fatty liver disease: What to know about the new findings
- The phase 3 ESSENCE trial evaluated the effects of semaglutide in 800 adults with metabolic dysfunction-associated steatohepatitis who had stage 2 or 3 liver fibrosis over a 72-week period.
- MASH is a chronic liver disease linked to excess fat and inflammation that can progress to cirrhosis and liver failure if untreated, affecting about one in 20 US adults.
- The trial found semaglutide led to improvements including 62.9% of participants achieving steatohepatitis resolution without fibrosis worsening and 36.8% showing fibrosis improvement versus placebo.
- Arun Sanyal, lead author of the ESSENCE trial, noted that the first phase of the study highlights how weekly semaglutide 2.4 mg positively impacts important liver tissue characteristics, potentially helping to prevent the advancement to cirrhosis and severe liver disease.
- Novo Nordisk has applied for FDA approval of semaglutide for MASH with priority review and expects the drug to offer a new option to prevent cirrhosis and related complications.
61 Articles
61 Articles
Fat jabs can treat liver disease affecting one in five people, finds trial
FAT jabs can treat a liver disease affecting one in five people, a trial found. Semaglutide cut inflammation in two thirds of patients with non-alcoholic fatty liver disease. GettyFat jabs can cut inflammation in two thirds of patients with non-alcoholic fatty liver disease[/caption] Nonalcoholic Fatty Liver Disease (NAFLD) a buildup of fat in the liver The medicine is used in weight-loss injection Wegovy and diabetes treatment Ozempic. Fatty li…
Chatham Star Tribune
ESSENCE phase 3 trial of semaglutide showed significant improvements at 72 weeks in adults with MASH, published in NEJM
Results of part 1 of the ESSENCE phase 3 trial, published in The New England Journal of Medicine, demonstrated that a greater proportion of patients with MASH achieved resolution of steatohepatitis with no worsening of liver fibrosis compared to placebo.…
Wegovy treated a serious form of liver disease in a major clinical trial
The weight loss drug Wegovy treated a serious form of liver disease in about two-thirds of patients in a major clinical trial, according to the findings published Wednesday in the New England Journal of Medicine.
Coverage Details
Bias Distribution
- 45% of the sources lean Left
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
